Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients

View ORCID ProfileAzza Shoaibi, Stephen Fortin, Rachel Weinstein, View ORCID ProfileJesse Berlin, Patrick Ryan
doi: https://doi.org/10.1101/2020.09.23.20199463
Azza Shoaibi
1 Janssen Research & Development, LLC, Titusville, NJ, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Azza Shoaibi
  • For correspondence: ashoaibi@its.jnj.com
Stephen Fortin
1 Janssen Research & Development, LLC, Titusville, NJ, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sfortin1@its.jnj.com
Rachel Weinstein
1 Janssen Research & Development, LLC, Titusville, NJ, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rweinst1@its.jnj.com
Jesse Berlin
2 Johnson & Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jesse Berlin
  • For correspondence: jberlin@its.jnj.com
Patrick Ryan
1 Janssen Research & Development, LLC, Titusville, NJ, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pryan4@its.jnj.com
  • Abstract
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background: Famotidine has been posited as a potential treatment for COVID-19. We compared the incidence of COVID-19 outcomes (i.e., death; and death or intensive services use) among hospitalized famotidine users vs. proton pump inhibitors (PPIs) users, hydroxychloroquine users or famotidine non-users separately. Methods: We constructed a retrospective cohort study using data from COVID-19 Premier Hospital electronic health records. Study population were COVID-19 hospitalized patients aged 18 years or older. Famotidine, PPI and hydroxychloroquine exposure groups were defined as patients dispensed any medication containing one of the three drugs on the day of admission. The famotidine non-user group was derived from the same source population with no history of exposure to any drug with famotidine as an active ingredient prior to or on the day of admission. Time-at-risk was defined based on the intention-to-treat principle starting 1 day after admission to 30 days after admission. For each study comparison group, we fit a propensity score (PS) model through large-scale regularized logistic regression. The outcome was modeled using a survival model. Results: We identified 2193 users of PPI, 5950 users of the hydroxychloroquine, 1816 users of famotidine and 26,820 non-famotidine users. After PS stratification, the hazard ratios for death were as follows: famotidine vs no famotidine HR 1.03 (0.89-1.18); vs PPIs: HR 1.14 (0.94-1.39); vs hydroxychloroquine:1.03 (0.85-1.24). Similar results were observed for the risk of death or intensive services use. Conclusion: We found no evidence of a reduced risk of COVID-19 outcomes among hospitalized COVID-19 patients who used famotidine compared to those who did not or compared to PPI or hydroxychloroquine users.

Competing Interest Statement

AS, SF, RW, PBR are employees of Janssen Research and Development and shareholder of Johnson & Johnson, the product manufacturer of famotidine. JB is an employee and shareholder of Johnson & Johnson

Clinical Protocols

https://github.com/ohdsi-studies/Covid19EstimationFamotidine/blob/master/Protocol/Covid19EstimationFamotidineProtocol.pdf

Funding Statement

No external funding was received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Reviewed by New England Institutional Review Board (IRB) and was determined to be exempt from broad IRB approval, as this research project did not involve human subject research.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

To protect patient privacy, all patient-level data were maintained securely behind institutional firewalls. Analysis code was executed by researchers, which generated only aggregate summary statistics (cohort counts, model coefficients) which were then synthesized in preparation of this manuscript. All aggregate summary statistics produced have been made publicly available at: https://data.ohdsi.org/Covid19EstimationFamotidine/

https://data.ohdsi.org/Covid19EstimationFamotidine/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted September 24, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
Azza Shoaibi, Stephen Fortin, Rachel Weinstein, Jesse Berlin, Patrick Ryan
medRxiv 2020.09.23.20199463; doi: https://doi.org/10.1101/2020.09.23.20199463
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
Azza Shoaibi, Stephen Fortin, Rachel Weinstein, Jesse Berlin, Patrick Ryan
medRxiv 2020.09.23.20199463; doi: https://doi.org/10.1101/2020.09.23.20199463

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Gastroenterology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (415)
  • Dentistry and Oral Medicine (70)
  • Dermatology (48)
  • Emergency Medicine (144)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4861)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (676)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (630)
  • Health Policy (321)
  • Health Systems and Quality Improvement (206)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5343)
  • Intensive Care and Critical Care Medicine (331)
  • Medical Education (93)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (686)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (208)
  • Oncology (440)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (781)
  • Public and Global Health (1817)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)